Biocept is a molecular oncology diagnostics company that develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid. Co. has commercialized its CNSide and Target Selector assays for detecting and characterizing various different carcinomas derived from epithelial cells of solid organs such as: breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. In addition, Co. has launched RT-PCR Coronavirus testing at its laboratory. The BIOC stock yearly return is shown above.
The yearly return on the BIOC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BIOC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|